These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 24931661)

  • 1. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Lee P; Eung Kim C; Yoon Kim C; Lin WW; Habil H; Dyachkova Y; Mcbride M; Dossenbach M
    Int J Psychiatry Clin Pract; 2008; 12(3):215-27. PubMed ID: 24931661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Bitter I; Treuer T; Dyachkova Y; Martenyi F; McBride M; Ungvari GS
    Eur Neuropsychopharmacol; 2008 Mar; 18(3):170-80. PubMed ID: 17884390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
    Bitter I; Czobor P; Dossenbach M; Volavka J
    Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The intercontinental schizophrenia outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America].
    Brunner E; Gargoloff P; Caro O; González C; Landa E; González CH; Barahona A; Soria D; Tamayo J; Rovner J; Adrianzen C; Silva H; Hodge A; O'Halloran R; Assunção SS;
    Actas Esp Psiquiatr; 2006; 34(1):16-27. PubMed ID: 16525901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Dyachkova Y; Pirildar S; Anders M; Khalil A; Araszkiewicz A; Shakhnovich T; Akram A; Pecenak J; McBride M; Treuer T
    Eur Psychiatry; 2006 Jun; 21(4):251-8. PubMed ID: 16530390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO).
    Treuer T; Anders M; Bitter I; Dobre G; Pecenak J; Dyachkova Y; Harrison G; O'Mahoney J
    Int J Psychiatry Clin Pract; 2006; 10(2):78-90. PubMed ID: 24940957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study.
    Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Madrigal M; Hernández G
    Clin Drug Investig; 2002 Sep; 22(9):609-622. PubMed ID: 29492855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
    Haro JM; Salvador-Carulla L
    CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia Outpatient Health Outcomes study: twelve-month findings.
    Novick D; Ascher-Svanum H; Haro JM; Bertsch J; Takahashi M
    Pragmat Obs Res; 2012; 3():27-40. PubMed ID: 27774015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.
    Ye W; Ascher-Svanum H; Tanji Y; Flynn JA; Takahashi M; Conley RR
    Neuropsychiatr Dis Treat; 2012; 8():259-66. PubMed ID: 22745559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intercontinental schizophrenia outpatient health outcomes (ic-soho) study: baseline clinical and functional characteristics and antipsychotic use patterns in the central and eastern europe (cee) region.
    Korb FA; Trzebiatowska I; Janikova E; Winkler-Skaza V; Ilies D; Peciukaitiene D; Anders M; Simon L; Smulevich AB; Dossenbach M
    Psychiatr Danub; 2003 Dec; 15(3-4):163-74. PubMed ID: 19114924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder.
    Gao K; Mackle M; Cazorla P; Zhao J; Szegedi A
    Neuropsychiatr Dis Treat; 2013; 9():1145-57. PubMed ID: 24003306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.
    Ascher-Svanum H; Zhu B; Faries DE; Lacro JP; Dolder CR; Peng X
    Patient Prefer Adherence; 2008 Feb; 2():67-77. PubMed ID: 19920946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine.
    Peralta V; Cuesta MJ
    Prim Care Companion J Clin Psychiatry; 2010; 12(2):. PubMed ID: 20694120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Ascher-Svanum H; Flynn JA; Tanji Y; Takahashi M
    Clinicoecon Outcomes Res; 2012; 4():13-9. PubMed ID: 22347801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine.
    Nagaraj AK; Pai NB; Rao S
    Indian J Psychiatry; 2009; 51(4):265-71. PubMed ID: 20048451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.